Dark

Check out our API

GHRS
GH Research PLC
stock NASDAQ

At Close

May 9, 2025 3:59:54 PM EDT

10.43USD-3.426%(-0.37)70,405

10.37Bid 10.49Ask 0.12Spread

Pre-market

May 5, 2025 8:14:30 AM EDT

11.34USD+5.000%(+0.54)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Dec 30, 2021

09:37AM EST 2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around? Benzinga

Dec 6, 2021

06:18PM EST Psychedelic Medicine: 5-MeO-DMT Formula For Treatment-Resistant Depression Has Positive Trial Results Benzinga

02:16PM EST GH Research Announces Positive Trial Results For Treatment-Resistant Depression Benzinga

10:15AM EST GH Research Posts Data From Treatment-Resistant Depression Trial Benzinga

07:22AM EST GH Research Q3 EPS $(0.04) Beats $(0.10) Estimate Benzinga

07:10AM EST GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2021 and gave updates on its business. GlobeNewswire Inc

07:03AM EST GH Research Says its Phase 2 Trial of GH001 in Treatment-Resistant Depression Met its Primary and Secondary Endpoint Benzinga

07:00AM EST GH Research Announces Successful Outcome of the Phase 2 part of GlobeNewswire Inc

Nov 16, 2021

03:54PM EST Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying Benzinga

Oct 29, 2021

02:38PM EDT Mid-Afternoon Market Update: Gold Down 1%; A10 Networks Shares Gain Following Q3 Results Benzinga

Oct 18, 2021

01:37PM EDT Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation Benzinga

Oct 13, 2021

04:25PM EDT There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are Benzinga

Sep 23, 2021

05:29PM EDT GH Research Q2 2021 G&A Expenses $719K Benzinga

05:25PM EDT GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. GlobeNewswire Inc

Aug 9, 2021

08:26PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Jul 23, 2021

06:10PM EDT Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To 'Psychedelics Renaissance' Benzinga

05:04PM EDT Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To "Psychedelics Renaissance" Benzinga

Jul 20, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 Benzinga

08:53AM EDT Cowen & Co. Initiates Coverage On GH Research with Outperform Rating Benzinga

08:01AM EDT JMP Securities Initiates Coverage On GH Research with Outperform Rating, Announces Price Target of $35 Benzinga

07:56AM EDT Stifel Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $26 Benzinga

06:50AM EDT Canaccord Genuity Initiates Coverage On GH Research with Buy Rating, Announces Price Target of $35 Benzinga

Jul 7, 2021

01:51PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Jul 3, 2021

12:32PM EDT Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies Benzinga

Jun 25, 2021

11:27AM EDT GH Research Shares Open For Trade At $22; IPO Priced At $16/Share Benzinga

11:21AM EDT GH Research Shares Indicating $21 On 179K Shares Benzinga

10:58AM EDT GH Research Shares Indicating $22.40 Benzinga

09:09AM EDT GH Research Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $16/Share Benzinga

Share